Free Trial

Amundi Cuts Position in Doximity, Inc. (NASDAQ:DOCS)

Doximity logo with Medical background
Remove Ads

Amundi lowered its holdings in shares of Doximity, Inc. (NASDAQ:DOCS - Free Report) by 93.7% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 11,656 shares of the company's stock after selling 172,971 shares during the period. Amundi's holdings in Doximity were worth $641,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. FMR LLC boosted its stake in Doximity by 30.5% during the third quarter. FMR LLC now owns 6,837,733 shares of the company's stock worth $297,920,000 after acquiring an additional 1,598,602 shares in the last quarter. State Street Corp grew its stake in shares of Doximity by 2.5% in the 3rd quarter. State Street Corp now owns 3,693,982 shares of the company's stock valued at $160,947,000 after buying an additional 88,922 shares during the period. Geode Capital Management LLC increased its position in Doximity by 19.8% in the 3rd quarter. Geode Capital Management LLC now owns 2,856,984 shares of the company's stock valued at $124,503,000 after buying an additional 472,565 shares in the last quarter. Los Angeles Capital Management LLC raised its stake in Doximity by 33.7% during the 4th quarter. Los Angeles Capital Management LLC now owns 870,322 shares of the company's stock worth $46,466,000 after buying an additional 219,448 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Doximity by 3.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 778,524 shares of the company's stock worth $41,565,000 after acquiring an additional 25,523 shares in the last quarter. 87.19% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Insiders Place Their Bets

In other news, Director Timothy S. Cabral sold 20,000 shares of Doximity stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $57.62, for a total transaction of $1,152,400.00. Following the completion of the sale, the director now owns 6,360 shares in the company, valued at approximately $366,463.20. This trade represents a 75.87 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 37.40% of the company's stock.

Analyst Ratings Changes

A number of brokerages have commented on DOCS. Leerink Partnrs upgraded shares of Doximity from a "hold" rating to a "strong-buy" rating in a research note on Friday, February 7th. KeyCorp dropped their target price on Doximity from $70.00 to $65.00 and set an "overweight" rating on the stock in a report on Wednesday, January 8th. Leerink Partners upgraded Doximity from a "market perform" rating to an "outperform" rating and raised their price objective for the company from $60.00 to $90.00 in a research note on Friday, February 7th. Bank of America upped their target price on shares of Doximity from $54.00 to $57.00 and gave the stock a "neutral" rating in a research note on Monday, January 6th. Finally, Canaccord Genuity Group raised their price target on shares of Doximity from $60.00 to $71.00 and gave the company a "hold" rating in a research report on Friday, February 7th. Eleven equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, Doximity presently has an average rating of "Moderate Buy" and a consensus target price of $64.22.

Get Our Latest Stock Report on DOCS

Doximity Trading Up 5.4 %

Shares of Doximity stock traded up $3.40 during trading on Monday, hitting $66.39. The stock had a trading volume of 3,877,737 shares, compared to its average volume of 1,891,424. The firm has a market cap of $12.39 billion, a price-to-earnings ratio of 66.39, a P/E/G ratio of 4.10 and a beta of 1.34. Doximity, Inc. has a 12 month low of $22.96 and a 12 month high of $85.21. The business's 50-day moving average is $64.42 and its 200 day moving average is $53.63.

Doximity Profile

(Free Report)

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.

Read More

Institutional Ownership by Quarter for Doximity (NASDAQ:DOCS)

Should You Invest $1,000 in Doximity Right Now?

Before you consider Doximity, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Doximity wasn't on the list.

While Doximity currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

Recent Videos

Time to Buy SoFi? Fintech’s Next Big Move
3 Chip Stocks Primed for a Comeback—Have They Found the Bottom?
Why Palantir’s Future Just Got a Massive Boost

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads